Techna Institute and Radiation Medicine Program,
Princess Margaret Cancer Center,
STTARR Innovation Center,
Techna Institute and Radiation Medicine Program, Princess Margaret Cancer Center
Jinzi Zheng has not added Biography.
If you are Jinzi Zheng and would like to personalize this page please email our Author Liaison for assistance.
Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications.
Investigative radiology Mar, 2006 | Pubmed ID: 16481918
In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications.
Pharmaceutical research Jun, 2007 | Pubmed ID: 17373581
Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model.
Molecular pharmaceutics Mar-Apr, 2009 | Pubmed ID: 19298061
Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Cancer research Jun, 2009 | Pubmed ID: 19458065
Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG-PET and histology.
Contrast media & molecular imaging May-Jun, 2010 | Pubmed ID: 20586032
Differential expression of the 18 kDa translocator protein (TSPO) by neoplastic and inflammatory cells in mouse tumors of breast cancer.
Molecular pharmaceutics Jun, 2011 | Pubmed ID: 21417480
APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
Journal of controlled release : official journal of the Controlled Release Society Sep, 2011 | Pubmed ID: 21640146
The translocator protein ligand [¹⁸F]DPA-714 images glioma and activated microglia in vivo.
European journal of nuclear medicine and molecular imaging May, 2012 | Pubmed ID: 22270507
A novel minimally invasive technique to create a rabbit VX2 lung tumor model for nano-sized image contrast and interventional studies.
PloS one , 2013 | Pubmed ID: 23840673
The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a rat 9L intracranial glioma model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine Dec, 2013 | Pubmed ID: 24212976
A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors.
PloS one , 2013 | Pubmed ID: 24312530
Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice.
Journal of controlled release : official journal of the Controlled Release Society Mar, 2014 | Pubmed ID: 24440663
A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.
Nanomedicine : nanotechnology, biology, and medicine Jan, 2015 | Pubmed ID: 25200610
Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates.
EJNMMI research , 2015 | Pubmed ID: 25918676
Contrast Agent Mass Spectrometry Imaging Reveals Tumor Heterogeneity.
Analytical chemistry Aug, 2015 | Pubmed ID: 26138213
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).
Molecular cancer therapeutics Sep, 2015 | Pubmed ID: 26162690
Evaluation of PET Imaging Performance of the TSPO Radioligand [(18)F]DPA-714 in Mouse and Rat Models of Cancer and Inflammation.
Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging Jul, 2015 | Pubmed ID: 26194010
A multimodal nano agent for image-guided cancer surgery.
Biomaterials Oct, 2015 | Pubmed ID: 26218742
Longitudinal tumor hypoxia imaging with [(18)F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity.
EJNMMI research Dec, 2015 | Pubmed ID: 26481012
Ambient Mass Spectrometry Imaging with Picosecond Infrared Laser Ablation Electrospray Ionization (PIR-LAESI).
Analytical chemistry Nov, 2015 | Pubmed ID: 26561279
Yannan N. Dou1,
Robert A. Weersink2,5,
Warren D. Foltz5,6,
Jinzi Zheng5,6,
Naz Chaudary7,
David A. Jaffray2,3,4,5,6,
Christine Allen1
1Leslie Dan Faculty of Pharmacy, University of Toronto,
2Department of Radiation Oncology, University of Toronto,
3Medical Biophysics, University of Toronto,
4Institute of Biomaterials & Biomedical Engineering, University of Toronto,
5Techna Institute and Radiation Medicine Program, Princess Margaret Cancer Center, University Health Network,
6STTARR Innovation Center, University Health Network,
7Ontario Cancer Institute, University Health Network
Shawn Stapleton1,2,3,
Daniel Mirmilshteyn2,
Jinzi Zheng3,4,
Christine Allen2,4,5,
David A. Jaffray1,2,3,4,5,6
1Department of Medical Biophysics, University of Toronto,
2Leslie Dan Faculty of Pharmacy, University of Toronto,
3STTARR Innovation Centre, Princess Margaret Cancer Centre,
4Institute of Biomaterials and Biomedical Engineering, University of Toronto,
5Techna Institute, University Health Network,
6Radiation Medicine Program, Princess Margaret Cancer Centre
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados